Inventor · disambiguated record
Maria Bednarek
Also filed as: BEDNAREK MARIA · BEDNAREK MARIA A · BEDNAREK MARIA ALEKSANDRA
14 granted patents·12 pending applications·92 citations·filing 2001–2025
89Inventor score
Top patents by PatentIndex Score
26 records- 0192US6967237B2Ghrelin analogsMERCK & CO INC·Filed 2001·Granted Nov 22, 2005·48 cites·14 claims
- 0287US6693165B2Cyclic peptides as potent and selective melanocortin-4 receptor antagonistsMERCK & CO INC·Filed 2001·Granted Feb 17, 2004·35 cites·8 claims
- 0375US6960646B2Cyclic peptides as potent and selective melanocortin-4 receptors agonistsMERCK & CO INC·Filed 2002·Granted Nov 1, 2005·3 cites·10 claims
- 0471US11230584B2Glucagon/GLP-1 agonists for the treatment of obesityMEDIMMUNE LTD·Filed 2019·Granted Jan 25, 2022·0 cites·13 claims
- 0569US9714277B2Pegylated glucagon and GLP-1 co-agonists for the treatment of obesityMEDIMMUNE LTD·Filed 2014·Granted Jul 25, 2017·1 cites·6 claims
- 0668US7273846B2Selective melanin-concentrating hormone type-1 receptor agonistsMERCK & CO INC·Filed 2003·Granted Sep 25, 2007·4 cites·13 claims
- 0768US2022098265A1Glucagon/glp-1 agonists for the treatment of obesityMEDIMMUNE LTD·Filed 2021·Application pending·0 cites
- 0866US9765130B2Glucagon/GLP-1 agonists for the treatment of obesityMEDIMMUNE LTD·Filed 2013·Granted Sep 19, 2017·1 cites·19 claims
- 0963US2025353891A1Glp-1 and glucagon dual agonist peptides with improved biological stabilityMEDIMMUNE LTD·Filed 2023·Application pending·0 cites
- 1063US2023357348A1Glp-1 and glucagon dual agonist peptides with improved biological stabilityMEDIMMUNE LTD·Filed 2023·Application pending·0 cites
- 1160US12371464B2Polypeptides and uses thereofMEDIMMUNE LTD·Filed 2021·Granted Jul 29, 2025·0 cites·7 claims
- 1260US2022041681A1Glucagon and glp-1 co-agonists for the treatment of obesityMEDIMMUNE LTD·Filed 2021·Application pending·0 cites
- 1358US10676517B2Glucagon and GLP-1 co-agonists for the treatment of obesityMEDIMMUNE LTD·Filed 2017·Granted Jun 9, 2020·0 cites·15 claims
- 1458US2021221866A1Protease-resistant lipidated glp-1 analogsMEDIMMUNE LTD·Filed 2021·Application pending·0 cites
- 1558US2010075907A1Neuromedin u receptor agonists and uses thereofMARSH DONALD J·Filed 2009·Application pending·0 cites
- 1657US10556939B2Glucagon/GLP-1 agonists for the treatment of obesityMEDIMMUNE LTD·Filed 2017·Granted Feb 11, 2020·0 cites·3 claims
- 1754US2025289860A1Polypeptides and uses thereofMEDIMMUNE LTD·Filed 2025·Application pending·0 cites
- 1853US2020354426A1Glucagon and glp-1 co-agonists for the treatment of obesityMEDIMMUNE LTD·Filed 2020·Application pending·0 cites
- 1950US2007244048A1Neuromedin U receptor agonists and uses thereofMARSH DONALD J·Filed 2007·Application pending·0 cites
- 2049US2020079833A1Protease-resistant lipidated glp-1 analogsMEDIMMUNE LTD·Filed 2019·Application pending·0 cites
- 2148US10414811B2Protease-resistant lipidated GLP-1 analogsMEDIMMUNE LTD·Filed 2016·Granted Sep 17, 2019·0 cites·15 claims
- 2246US2016318987A1Protease resistant peptidesMEDIMMUNE LTD·Filed 2014·Application pending·0 cites
- 2345US7220720B2Melanin-concentrating hormone analogsMERCK & CO INC·Filed 2001·Granted May 22, 2007·0 cites·18 claims
- 2445US2016185837A1Gip and glp-1 receptor dual-agonists for the treatment of diabetesMEDIMMUNE LTD·Filed 2014·Application pending·0 cites
- 2542US7335723B2Melanin-concentrating hormone antagonistsMERCK & CO INC·Filed 2002·Granted Feb 26, 2008·0 cites·14 claims
- 2642US7314861B2Melanin-concentrating hormone analogsMERCK & CO INC·Filed 2002·Granted Jan 1, 2008·0 cites·20 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →